18:45:11 EDT Tue 16 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z0.173.69·74.250.274.13-0.40-0.59,026.7667,27334,13674.36  75.10  73.84580.59  53.2217:33:3606:5915 min RT 2¢

Recent Trades - Last 10 of 34136
Time ETExPriceChangeVolume
17:33:36Z74.00-0.5311
17:33:36Z74.00-0.531
17:33:36Z74.00-0.531
17:15:00Z74.03-0.504
17:11:19Z74.03-0.501
16:55:57Z74.12-0.411
16:34:06Z74.13-0.403,899
16:31:39Z74.13-0.409,530
16:28:09Z74.13-0.403,631
16:23:56Z74.13-0.40606

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2022-08-16 06:59U:BMYNews ReleaseBristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
2022-08-10 06:45U:BMYNews ReleaseBristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
2022-08-03 16:16U:BMYNews ReleaseBristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
2022-07-29 06:59U:BMYNews ReleaseBristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
2022-07-27 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Second Quarter Financial Results for 2022
2022-07-22 06:59U:BMYNews ReleaseBristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
2022-07-21 06:59U:BMYNews ReleaseBristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry
2022-07-20 06:59U:BMYNews ReleaseBristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities